Latest insights

From uncertainty to growth: why invest in healthcare?

ESG, SRI, Oncology, Healthcare
As we enter the month of October, investors are faced with an obvious question: is the time right for new investments in the oncology sector? Pasquale Sansone, Senior Biotechnology Analyst, shares his analysis and convictions.
  • Fixed Income, Charudatta Shende

    Bond market opportunities: The Return of Slope

    The global rates landscape is entering a decisive new phase as the long-standing flatness of yield curves gives way to steepness that has not been seen since 2011. The term premium, the additional interest by bondholders investing in longer-dated bonds versus short-term bonds, is back after an absence of many years.
  • ESG, SRI

    Active Ownership: Persistence Pays

    If some elements of our annual 2024 Annual Engagement and Voting Review sound familiar, that’s no coincidence. To maximize our impact, we focus on long-term core topics. Engagement and voting are central to our investment process, extending beyond the important responsibility of the investments we already hold.
9 results found
Show me
  • Topic
  • Expert
Show me
  • Topic
from
  • Expert
9 results found
Corporate

Candriam Thematic Global Equity Team Update

Candriam announces an important leadership transition within its Thematic Global Equity platform, and related fund management changes to its healthcare strategies, including strategies investing in the biotechnology sector, life care and in the fight against cancer.
Corporate

Candriam statement on its investments in Russia

First and foremost, our thoughts are with the Ukrainian people at this terrible and uncertain time. Candriam and its employees are deeply saddened by the events we are seeing unfold, and deplore the human tragedy this brings.
Load more

Find it fast

Get information faster with a single click

Get insights straight to your inbox